Adaptive Biotechnologies Q2 EPS $(0.33), Inline, Sales $48.93M Beat $45.48M Estimate
Portfolio Pulse from saritha@benzinga.com
Adaptive Biotechnologies reported Q2 losses of $(0.33) per share, in line with analyst estimates. This is a 10.81% improvement from the same period last year. The company's quarterly sales of $48.93M beat the analyst consensus estimate of $45.48M by 7.58%, marking a 12.06% increase from last year.
August 04, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adaptive Biotechnologies reported Q2 earnings in line with estimates and sales beating estimates. This could potentially have a positive impact on the stock.
Adaptive Biotechnologies reported Q2 earnings that met analyst expectations and sales that exceeded expectations. This indicates a strong financial performance, which could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100